Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas^® HBV Test for Use on the Cobas^® 4800 System

• Published in: Microorganisms
• Main Authors: Valérie Ortonne, Mélanie Wlassow, Magali Bouvier-Alias, Giovana Melica, Jean-Dominique Poveda, Syria Laperche, Jean-Michel Pawlotsky, Stephane Chevaliez
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Subjects: hepatitis B virus; HBV DNA; HBV monitoring; real-time PCR; hepatitis B infection diagnosis
• Online Access: https://www.mdpi.com/2076-2607/9/3/573

(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection. The aim of this study was to assess the analytical and clinical performance of the cobas^® HBV Test on the cobas^® 4800 System. (2) Methods: Standard panel and clinical specimens were tested in parallel with three different real-time commercial PCR assays including the cobas ^® HBV Test, the Cobas^® AmpliPrep/Cobas^® TaqMan HBV Test v2.0 and Alinity™ <i>m</i> HBV assay. (3) Results: The specificity of the cobas^® HBV Test was 97.9%. The limit of detection was estimated to be 2.1 IU/mL. Intra-assay and interassay coefficients of variation varied from 0.14% to 1.92% and 2.16% to 12.02%, respectively. HBV DNA levels in patients infected with different HBV genotypes strongly correlated with those measured by the two other commercial comparators assays. (4) Conclusions: The cobas^® HBV Test can be confidently used to detect and accurately quantify HBV DNA in clinical practice as well as in clinical trials with the new anti-HBV drugs currently in development.